Benzinga | Oct 16, 2020 05:54AM EDT

Piper Sandler Initiates Coverage On Fulcrum Therapeutics with Overweight Rating, Announces Price Target of $22

Piper Sandler analyst Edward Tenthoff initiates coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight rating and announces Price Target of $22.